Sign In
Buy ALDX
$1.86
+0.220 (+13.41%)
At Close: Jun 03, 2026
Did Aldeyra Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate– ADLX
07:15pm, Thursday, 03'rd Apr 2025
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ:ADLX) c
NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Comp
Aldeyra Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ADLX
05:15pm, Thursday, 03'rd Apr 2025
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ:ADLX) c
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX
05:03pm, Thursday, 03'rd Apr 2025
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such invest
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ:ADLX) c
Lost Money on Aldeyra Therapeutics, Inc. (ADLX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
03:15pm, Thursday, 03'rd Apr 2025
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ:ADLX) c
Aldeyra Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ADLX
02:45pm, Thursday, 03'rd Apr 2025
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ:ADLX) c
NEW YORK--(BUSINESS WIRE)---- $ALDX #ALDX--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations o
Shares of Aldeyra Therapeutics are down nearly 75% today. Block & Leviton is investigating ALDX for potential securities fraud. Investors should reach out.
Aldeyra Therapeutics tanks as FDA rejects investigational dry eye disease therapy
11:06am, Thursday, 03'rd Apr 2025
Aldeyra Therapeutics (NASDAQ:ALDX) shares plummeted more than 70% after the biotechnology company received a letter of refusal from the Food and Drug Administration (FDA) for its investigational dry e
FDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns
09:37am, Thursday, 03'rd Apr 2025
The U.S. Food and Drug Administration (FDA) on Thursday issued a Complete Response Letter for Aldeyra Therapeutics, Inc.'s ALDX resubmission of the New Drug Application (NDA) of reproxalap, an invest
US FDA declines to approve Aldeyra's eye disease drug
08:10am, Thursday, 03'rd Apr 2025
The U.S. Food and Drug Administration has declined to approve Aldeyra Therapeutics' treatment for dry eye disease, the company said on Thursday.
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
Aldeyra Therapeutics Is Severely Undervalued Before PDUFA
04:09pm, Wednesday, 05'th Mar 2025
Aldeyra's reproxalap faced an FDA setback but showed positive trial results, leading to a resubmitted NDA with a PDUFA date of April 2025. Despite a controversial deal with AbbVie, Aldeyra remains fin
